Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction

Am J Cardiol. 2000 Dec 15;86(12):1378-9, A5. doi: 10.1016/s0002-9149(00)01248-0.

Abstract

The mechanical force of injection at 90 minutes opens 13.4% of occluded arteries, but overall, only 2.4% of all culprit arteries (already open and occluded combined) are opened. Thus, although some arteries are opened by the force of hand injection, the frequency of mechanical opening among all arteries is low, and hand injections appear to alter current 80% patency rates by approximately 2.5%.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abciximab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Contrast Media
  • Coronary Angiography*
  • Coronary Circulation / physiology
  • Coronary Vessels / pathology
  • Coronary Vessels / physiopathology*
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Immunoglobulin Fab Fragments / administration & dosage
  • Immunoglobulin Fab Fragments / therapeutic use
  • Injections, Intra-Arterial
  • Myocardial Infarction / diagnostic imaging*
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / physiopathology
  • Odds Ratio
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Prospective Studies
  • Rheology
  • Stress, Mechanical
  • Tenecteplase
  • Thrombolytic Therapy*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / therapeutic use
  • Vascular Patency / physiology*

Substances

  • Antibodies, Monoclonal
  • Contrast Media
  • Fibrinolytic Agents
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tissue Plasminogen Activator
  • Tenecteplase
  • Abciximab